Search

Your search keyword '"Arkkila, P."' showing total 283 results

Search Constraints

Start Over You searched for: Author "Arkkila, P." Remove constraint Author: "Arkkila, P."
283 results on '"Arkkila, P."'

Search Results

3. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

4. Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: A meta-analysis

6. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease

8. Cross-Sectional and Longitudinal Associations between Quality of Parent-Child Interaction and Language Ability in Preschool-Age Children with Developmental Language Disorder

9. Structure of Cognitive Functions in Monolingual Preschool Children with Typical Development and Children with Developmental Language Disorder

10. Multidisciplinary behavioral therapy reduces rumination.

11. Language Acquisition of Early Sequentially Bilingual Children Is Moderated by Short-Term Memory for Order in Developmental Language Disorder: Findings from the HelSLI Study

12. L2 Vocabulary Acquisition of Early Sequentially Bilingual Children with TD and DLD Affected Differently by Exposure and Age of Onset

15. Both Individual and Group-Based Neuropsychological Interventions of Dyslexia Improve Processing Speed in Young Adults: A Randomized Controlled Study

16. Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial

18. P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

24. Ruokatorvi- ja mahasyövän riskiin voidaan vaikuttaa

29. DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn’s Disease and Ulcerative Colitis

31. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

32. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

33. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

38. Microbiota and mucosal gene expression of fecal microbiota transplantation or placebo treated patients with chronic pouchitis

39. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group

44. OC.05.5 OBETICHOLIC ACID TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: A SECONDARY ANALYSIS OF THE REGENERATE STUDY ACROSS FIBROSIS STAGES

45. Obeticholic acid treatment in patients with non-alcoholic steatohepatitis: a secondary analysis of the REGENERATE study across fibrosis stages

46. Maha-suolikanavan yläosan tähystystoimenpiteet

47. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug

48. Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug

49. Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed

Catalog

Books, media, physical & digital resources